Boehringer Ingelheim and Lilly initiate first ever...
Business Wire IndiaBoehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study wil...